Compare Enveric Biosciences Inc (ENVB) vs Quantum Computing Inc (QUBT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Enveric Biosciences Inc vs Quantum Computing Inc — how do they compare? Enveric Biosciences Inc trades at $1.45 (market cap $6.80M), while Quantum Computing Inc trades at $7.44 (market cap $1.69B). The key difference: Quantum Computing Inc is far larger — about 248.5× Enveric Biosciences Inc's market cap, and Enveric Biosciences Inc is more actively traded (64,867 versus 7,991,522). Which is the better fit depends on your goals — on Pluang, investors hold Enveric Biosciences Inc for 14 Days and Quantum Computing Inc for 25 Days on average.
| ENVB | QUBT | |
|---|---|---|
Market Cap | $6.80M | $1.69B |
Volume | 64,867 | 7,991,522 |
Sector | Health | Technology |
52-Week High | $10.80 | $21.78 |
52-Week Low | $1.27 | $6.31 |
Typical Hold Time | 14 Days | 25 Days |
Enterprise Value | -$1.49M | $753.24M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ENVB trades at $1.52, up 1.67% with a bearish technical outlook despite recent earnings beats. The company shows no revenue but has improved quarterly EPS performance, with Q4 2025 turning positive. Analyst sentiment is bullish with 75% buy ratings, while technical indicators show selling pressure with 15 sell signals versus 1 buy.
Investment outlook remains speculative given negative profitability metrics and zero revenue, though patent developments and FDA guidance provide potential catalysts. Key risks include cash burn and clinical trial outcomes, while institutional support through financing offers near-term stability.
QUBT trades at $7.45, down 2.23% on the day, amid a bearish technical signal from moving averages but with oscillators suggesting potential short-term bullish momentum. The company is in a pre-profitability growth phase, with revenue projected to jump to $10 million in 2026 from $682,000 in 2025, though net losses remain substantial. Recent news highlights the launch of the Dirac-3S quantum system and a $42.5 million backlog, indicating commercial progress but ongoing execution risks.
The investment case hinges on QUBT's ability to scale its quantum computing technology and convert its backlog into sustainable revenue, with a consensus analyst price target of $17.33 implying significant upside. Key risks include persistent cash burn, intense competition, and the speculative nature of the quantum computing sector, requiring careful risk assessment by investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Enveric Biosciences Inc
Enveric Biosciences is a biotechnology company focused on developing next-generation psychedelic-inspired therapies for mental health and neuropsychiatric disorders.
Read more on ENVB →About Quantum Computing Inc
Quantum Computing Inc. is a company focused on providing accessible quantum computing and quantum-enhanced software solutions for complex problems. The company's technology is designed to run on both classical and quantum hardware, enabling businesses to explore the power of quantum computing today for applications in finance, drug discovery, and logistics. QUBT offers a platform that makes quantum algorithms and software available through the cloud, aiming to democratize access to this advanced computing paradigm.
Read more on QUBT →
